The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

The Center for Human Nutrition at the U of A is conducting a research study to learn more about the effects of protein on body composition and wellbeing in adults who will be starting medication for ...

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss ... Mounjaro, Zepbound, and others — and 1.7 million ...

However, unlike Mounjaro and Ozempic, Zepbound is FDA approved for weight loss in adults when combined with diet and lifestyle changes. While research is ongoing, a landmark 2022 study of more ...